Company: DVAX
Filing Date: 2025-04-17
Form Type: DEFC14A
Source: 0000930413-25-001273
Chunk: 53

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: DEFC14A
Chunk 53
---
 firmly believes that Dynavax’s executive compensation programs should reward our named executive
officers for performance, and that when key performance objectives are not achieved, the compensation of our named executive officers
should reflect as much. We believe that the compensation of our named executive officers, as disclosed in this proxy, reflects
this philosophy. In addition, our Compensation Committee believes that the compensation programs for our named executive officers
have been instrumental in helping Dynavax be able to attract, retain and motivate our executive team, thereby enabling our company
to be in a position to move forward with our business strategy.

Our Board is now asking our stockholders to indicate their support for the compensation of our named executive
officers as described in this proxy statement by casting a non-binding advisory vote “For” the following resolution:

“RESOLVED, that the compensation paid to Dynavax’s named executive officers,
as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and
narrative discussion, is hereby APPROVED.”

Although this vote is advisory and the outcome is not binding on our Board, the views expressed by our stockholders,
whether through this vote or otherwise, are important to us. As a result, the Board and the Compensation Committee will carefully
review the results of this vote, and they will consider these results in making future decisions about our executive compensation
programs and arrangements.

We expect that the next advisory vote on the compensation of our named executive officers will be held at
the 2026 Annual Meeting of Stockholders.

Vote Required

Approval of this advisory proposal requires the affirmative vote of the majority of shares present (either
virtually at the Annual Meeting or by proxy) and entitled to vote on the matter at the Annual Meeting. Abstentions have the same
effect as negative votes. Broker non-votes, if any, are counted towards a quorum but are not counted for any purpose in determining whether
this Proposal 2 has been approved.

<div align='center'>THE BOARD OF DIRECTORS RECOMMENDS

A VOTE “FOR” PROPOSAL 2.</div>

| 38 |

<div align='center'>PROPOSAL 3

RATIFICATION OF SELECTION OF

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

The Audit Committee has selected Ernst &
Young LLP (“Ernst & Young”) as our independent registered public accounting firm for the fiscal year ending December
31, 2025. Ernst & Young has audited our financial statements